FLJ37396 Inhibitors
The FLJ37396 Inhibitors chemical class comprises a set of compounds targeting key signaling pathways critical for FLJ37396 regulation. These inhibitors act on various kinases and signaling molecules, disrupting cellular cascades involved in FLJ37396 expression. TPCA-1 and AS602868 inhibit FLJ37396 by targeting IKK-2, a kinase involved in the NF-κB pathway. By blocking IKK-2, these compounds disrupt NF-κB activation, indirectly suppressing FLJ37396. BAY 11-7082 and JSH-23 also target NF-κB, impacting FLJ37396 through interference with NF-κB-mediated cellular processes. CAY10576 inhibits TAK1, affecting both the MAPK and NF-κB pathways, indirectly influencing FLJ37396 by interfering with upstream regulatory signals.
Wedelolactone inhibits IKK, another component of the NF-κB pathway, indirectly suppressing FLJ37396. GSK'963 targets TBK1, impacting the innate immune response and indirectly influencing FLJ37396 through interference with upstream regulatory signals. IMD-0354, MLN120B, BI605906, and sc-514 all inhibit IKK-2, affecting NF-κB activation, and subsequently, they indirectly influence FLJ37396 by interfering with NF-κB-mediated cellular processes. This diverse chemical class collectively interferes with multiple signaling pathways, highlighting potential strategies for modulating FLJ37396 expression in cellular contexts.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IKK-2 Inhibitor IV | 507475-17-4 | sc-203083 | 500 µg | $133.00 | 12 | |
TPCA-1 inhibits FLJ37396 by blocking IKK-2, a kinase involved in the NF-κB pathway. By disrupting NF-κB activation, it indirectly suppresses FLJ37396, as NF-κB regulates various cellular functions. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
BAY 11-7082 inhibits NF-κB activation, impacting FLJ37396 indirectly through interference with NF-κB-mediated cellular processes essential for FLJ37396 expression. | ||||||
NFκB Activation Inhibitor II, JSH-23 | 749886-87-1 | sc-222061 sc-222061C sc-222061A sc-222061B | 5 mg 10 mg 50 mg 100 mg | $214.00 $257.00 $1775.00 $2003.00 | 34 | |
JSH-23 inhibits NF-κB by specifically targeting p65, a subunit of NF-κB. Its action disrupts NF-κB-mediated cellular processes, indirectly affecting FLJ37396 regulation. | ||||||
Wedelolactone | 524-12-9 | sc-200648 sc-200648A | 1 mg 5 mg | $110.00 $337.00 | 8 | |
Wedelolactone inhibits IκB kinase (IKK), a component of the NF-κB pathway. By blocking IKK, it indirectly suppresses FLJ37396 through interference with NF-κB-mediated cellular processes. | ||||||
Imiquimod | 99011-02-6 | sc-200385 sc-200385A | 100 mg 500 mg | $67.00 $284.00 | 6 | |
IMD-0354 inhibits IKK-2, affecting NF-κB activation. By disrupting NF-κB signaling, it indirectly influences FLJ37396 through interference with NF-κB-mediated cellular processes. | ||||||
ML 120B Dihydrochloride | 783348-36-7 (free base) | sc-487759 | 5 mg | $380.00 | ||
MLN120B inhibits IKK-2, impacting NF-κB activation. Its action disrupts NF-κB signaling, indirectly affecting FLJ37396 by interfering with NF-κB-mediated cellular processes. | ||||||
BIIB 021 | 848695-25-0 | sc-364434 sc-364434A | 5 mg 25 mg | $128.00 $650.00 | ||
BI605906 inhibits IKK-2, affecting the NF-κB pathway. By disrupting NF-κB activation, it indirectly influences FLJ37396 through interference with NF-κB-mediated cellular processes. | ||||||
SC514 | 354812-17-2 | sc-205504 sc-205504A | 5 mg 10 mg | $67.00 $91.00 | 13 | |
SC-514 inhibits IKK-2, affecting NF-κB activation. Its action disrupts NF-κB signaling, indirectly influencing FLJ37396 by interfering with NF-κB-mediated cellular processes. | ||||||